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The need for coordination of European diabetes
research
Order! Order! Order in the House! So says the Speaker in
Parliament at Westminster, more or less effectively. But
European diabetes research has no speaker, no parliament,
no voice. There is a lack of collective vision and
coordination and unclear scientific rationale for public or
private funding of European diabetes research. It is hardly
surprising diabetes research in Europe is not as effective as
it could be, despite its historical and continuing strength.
We both recognise the importance of national sovereign-
ty and the right of each country to have its own research
policy. We are both weary of centralised authority with its
self-righteousness, numbing bureaucracy and cost-ineffec-
tiveness. We agree with A. A. Milne (creator of Winnie-the-
Pooh) who said: ‘One of the advantages of being disorderly
is that one is constantly making exciting discoveries.’ Yet
order and coordination in just the right dose can foster
creativity, discovery and improved return on investment.
Consider the situation in the USA. The National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK)
effectively oversees the national diabetes research effort
without compromising creativity. Political lobbying in
Congress in Washington and public advocacy throughout
the country have resulted in increased funding for the
NIDDK, with special appropriations amounting to some
$1 billion for diabetes research in the USA and indeed
beyond, including Europe. The NIDDK knows how much
is spent on diabetes research, in which specific area and by
which investigators. There is no agency in Europe with
such a detailed understanding of diabetes research in any
single country, let alone the entire continent.
DIAMAP: Road Map for Diabetes Research in Europe
The Unit for Medical and Public Health Research at the
Research Directorate of the European Commission under-
stands this problem and shares the view that European
diabetes research suffers from a lack of collective vision
and coordination. Last year the Commission acted in an
original and proactive way by inviting applications for the
development of a road map of European diabetes research
to be funded by a grant from the 7th Framework
Programme (FP7). The Alliance for European Diabetes
Research (EURADIA, http://www.euradia.org) applied and
was awarded just over €500,000 for its project, Road Map
for Diabetes Research in Europe (DIAMAP, grant number
FP7 200701, http://www.diamap.eu). Work on this 2 year
project started on 1 April 2008.
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The mission of DIAMAP is to identify overarching goals
in all areas of diabetes research and propose a road map
strategy for reaching these goals that will capitalise on
European expertise.
A project steering committee of high-profile EURADIA
members (representing patient organisations, academic
science and industry) will provide scientific guidance for
the project. The solid scientific backing of EURADIA and
patient input provide credibility for DIAMAP to assimilate
data on diabetes research currently being conducted in
Europe. Diabetes research has been broken down into six
major areas, each with its own group of experts chaired by
an investigator with comprehensive scientific knowledge in
the relevant focus area and more broadly in diabetes
research. A seventh group will deal with horizontal themes
that intersect the others, such as ethical and regulatory
issues as well as training.
DIAMAP: focused subgroups 
1. Genetics/Epidemiology
    Chair: N.J. Wareham, Cambridge, UK 
2. Islets/Immunology
    Chair: T. Mandrup-Poulsen, Copenhagen, Denmark 
3. Pathophysiology/Metabolism/Integrative physiology
    Chair: J.R. Zierath, Stockholm, Sweden 
4. Clinical science and care
    Chair: J.J. Nolan, Dublin, Ireland 
5. Complications (microvascular)
    Chair: P. Fioretto, Padua, Italy 
6. Complications (macrovascular)
    Chair: J. Skrha, Prague, Czech Republic 
7. Horizontal issues (cross-cutting issues for research 
    themes 1–6)
    Chair: P.E. Schwarz, Dresden, Germany
The Chairs of the focused subgroups make up DIA-
MAP’s Expert Advisory Board and will be driving the
scientific aspects of the project.
Research road maps developed by each group will be
compiled into a single report to provide the European
Commission, private funding agencies, industry and
researchers with a strategy to maximise the strengths and
opportunities for future diabetes research in Europe. All
stakeholders will participate through fora that will reinforce
the intended focus on the patient.
DIAMAP needs you!
A second important and related mission of DIAMAP will
be to undertake a wide survey of the current European
diabetes research landscape, from which expert opinion can
identify gaps and highlight strengths, to guide DIAMAP’s
road map strategy for diabetes research in Europe.
For this survey to be relevant and as complete as
possible, DIAMAP urgently needs input from as many
individuals as possible who are involved in any aspect of
diabetes research in Europe, from molecules to cells, organs
and living animals, from patients and clinical research to
patient care and education, health economics and health
policy. Everyone is concerned! DIAMAP needs you! Two
questionnaires can be found on the DIAMAP website
(http://www.diamap.eu). One relates to what research you
do (Research Questionnaire) and the other to the source of
funding (Funding Questionnaire). All independent inves-
tigators (group leaders) are asked to complete the Research
Questionnaire, regardless of their background and profes-
sion. The Funding Questionnaire should be completed by
organisations providing funding for diabetes research.
DIAMAP needs this information! Without these data,
DIAMAP will have no way of knowing who is doing what
in diabetes research and where in Europe. We will not know
who is paying for this research and how much is being
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spent. Moreover, this snapshot of the state of European
diabetes research today will provide a point of departure for
the road maps.
You need DIAMAP!
Without a massive response to these questionnaires,
DIAMAP will not be able to deliver on its promise. We
expect some of you to ask an obvious question followed by
a few equally predictable statements: Why me? I hate these
questionnaires and I am a very busy person. They can
manage without me. Wrong: we cannot manage without
you. This is a unique opportunity to make your voice
heard in the European diabetes research arena. This is a
way for you to ensure that your specific focus area is
taken seriously and that it is on the research map when
important decisions are taken about funding priorities. We
often complain that our particular field of research is not
well funded; now you can help change that! Others will
answer the questionnaires and if you (and colleagues
working in the same area as you) do not, the road maps
may be distorted and your research field may end up
being disadvantaged.
Putting our house in order: a model for others
A massive response will send a very strong signal to
politicians, civil servants and all stakeholders (including
private and public funding agencies as well as industry), that
we are all part of the larger ‘diabetes family’, alongside
patients and their families, and that we share the same
concerns. We must work together to put our house in order for
the benefit of all individuals with diabetes and for society
at large. DIAMAP is unique. It is the first time anything of
this kind has been attempted in any disease area in Europe.
Diabetes is taking the lead where others will follow. However,
this will only work if you, too, are fully involved.
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